ЛИТЕРАТУРА

1. Boguniewicz M, Leung DYM. Management of atopic dermatitis. In: Leung DYM, ed. Atopic dermatitis: from pathogenesis to treatment. Austin: R G Landes Co 1996:185-220

2. Loden M. Role of topical emollients and moisturizes in the treatment of dry skin barrier disorders. Am J Clin Dermatol 2003;4(11):771-788

3. Barnes P.J. New directions in allergic diseases: mechanism-based anti-inflammatory therapies. J Allergy Clin Immunol 2000;106:5-16

4. Атопический дерматит у детей: принципы наружной терапии. М.,2000

5. Guidelines of care for the use of topical glucocorticosteroids. Journal of the American Academy of Dermatology 1996;35(№4):615-620

6. Наружное лечение атопического дерматита у детей и взрослых с применением крема и аэрозоля Скин-Кап. Пособие для врачей. НВ Кунгуров, ММ Кохан, ЮВ Кениксфест, ЮГ Мирина. Екатеринбург 2003

7. НВ Кунгуров, ММ Кохан, ЮВ Кениксфест, ЮГ Мирина, СВ Ведерникова.Об оптимизации терапии больных атопическим дерматитом детей и взрослых. Вестн дерматол венерол 2004;3:23-29

8. Атопический дерматит. Новые подходы к профилактике и наружной терапии (ЮВ Сергеев –ред). М.:Медицина для всех, 2003

9. Lebwohl M. A comparison of once-daily application of mometasone furoate 0.1% cream compared with twice-daily hydrocortisone valerate 0.2% cream in pediatric atopic dermatitis patients who failed to respond to hydrocortisone: Mometasone furoate study group. Int J Dermatol 1999;38:604-606

10. Sidbury R, Hanifin JM. Old, new, and emerging therapies for atopic dermatitis. Dermatologic Clinics 2000;18(1):1-11

11. Макарова ИВ, Гайдук ИМ, Жиглинская ОВ, Мухарева ЭВ, Сухорукова ВГ. Применение крема алклометазона дипропионата 0,05% в терапии атопического дерматита у детей раннего возраста. Вопросы современной педиатрии 2004;4:84-87

12. Knoell KA, Greer KE. Atopic Dermatitis. Pediatrics in Review 1999;20(2):46-52

13. Meingassner J, Grassberger M, Fahrngruber H et al. A novel anti-inflammatory drug, SDZ ASM 981, for the topical and oral treatment of skin diseases: In vivo pharmacology. Br J Dermatol 1997;137:568-576

14. Grassberger M, Baumrucker T, Enz A et al. A novel anti-inflammatory drug, SDZ ASM 981, for the treatment of skin diseases: In vitro pharmacology. Br J Dermatol 1999;141:264-273

15. Wellington K. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002;62(5):817-840

16. Wahn U, Bos JD, Goodfield M et al. Efficacy and Safety of Pimecrolimus Cream in the Long-Term Management of Atopic Dermatitis in Children. Pediatrics 2002;110(№1)

17. Kapp A, Papp K et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a nonsteroid anti-inflammatory drug. J Allergy Clin Immunol 2002;110:277-284

18. Hauser C, Prins C, Lacour M. The role of infectious agents. In: Leung DYM, ed. Atopic dermatitis: from pathogenesis to treatment. Austin: R G Landes Co, 1996:67-112

19. Leyden J, Kligman A. The case for steroid-antibiotic combinations. Br J Dermatol 1977;96:179-187

20. Van Der Meer JB, Glazenburg EJ, Mulder PG et al. The management of moderate to severe atopic dermatitis in adults with topical fluticasone propionate. Br J Dermatol 1999;140:114-1121

21. Ring J. Plasma histamine concentrations in atopic eczema. Clin Allergy 1983;13:545

22. Ruzicka T, Gluck S. Cutaneous histamine levels and histamine releasability from the skin in atopic dermatitis and hyper-IgE syndrome. Arch Dermatol Res 1983;275:41

23. Berth-Jones J, Graham-Brown RAC. Treatment of itching in atopic eczema. Br Med J 1989;298:491-492

24. Klein PA, Clark RAF. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1989;135:1522-1525

25. Krause L, Shuster S. Mechanism of action of antipruritic drugs. BMJ 1983;287:1199

26. Behrendt BG, Ring J. Histamine, antihistamine and atopic eczema. Clin Exp Allergy 1990;20(Suppl 4):25-30

27. Klein PA, Clark RAF. An evidence-based review of the efficacy of antihistamines in relieving pruritus in atopic dermatitis. Arch Dermatol 1999;135:1522-1525

28. Wahlgren CF, Hagermark O et al. The antipruritic effect of a sedative and a non-sedative antihistamine in atopic dermatitis. Br J Dermatol 1990;122:545-551

29. Kemp JP. Tolerance induction to antihistamines: Is it a problem? Ann Allergy 1995;50:7-11

30. Гущин ИС, Каминка МЭ. Фенкарол. Значение в современной клинической практике и рекомендации по применению. М., 2004

31. Феденко ЕС. Фенкарол в комплексной терапии атопического дерматита и хронической крапивницы. Аллергия, астма и клин иммунология 2003(№6):10-12

32. Российский национальный согласительный документ по атопическому дерматиту. Атопический дерматит: применение антигистаминных препаратов.-М.: «Фармарус Принт» 2002.-24 с.

33. Marshall GD Jr. Therapeutic options in allergic disease: antihistamines as systemic antiallergic agents. J Allergy Clin Immunol 2000;106:303-309

34. Juhlin L. Nonclassical clinical indications for H1-receptor antagonists in dermatology. Allergy 1995;50:36-40

35. Гущин ИС. Аллергическое воспаление и его фармакологический контроль. М., Фармарус Принт, 1998

36. Behrendt BG, Ring J. Histamine, antihistamine and atopic eczema. Clin Exp Allergy 1990;20(Suppl 4):25-30

37. De Vos C. Zyrtec (Cetirizine) — Present Et Futur. Allerg Immunol 1989;21(1 Suppl):41-43

38. Diepgen TL. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, randomized, placebo-controlled trial (the ETAC trial) over 18 months. Pediatr Allergy Immunol Aug-2002;13(4):278-286

39. De Vos C. Zyrtec (Cetirizine) — Present Et Futur. Allerg Immunol 1989;21(1 Suppl):41-43

40. 26. Nassif A, Chan SC, Storrs FJ, et al. Abnormal skin irritancy in atopic dermatitis and in atopy without dermatitis. Arch Dermatol 1994;130:1402-1407

41. Sanda T, Yasue T, Oohashi M, et al. Effectiveness of house dust-mite allergen avoidance through clean room therapy in patients with atopic dermatitis. J Allergy Clin Immunol 1992;89:653-657

42. Bock SA, Atkins FM. Patterns of food hypersensitivity during sixteen years of double-blind, placebo-controlled food challenges. J Pediatr 1990;117:561-567

43. 16. Burks AW, Mallory SB, Williams LW, et al. Atopic dermatitis: Clinical relevance of food hypersensitivity reactions. J Pediatr 1998;113:447–451

44. Sampson HA. Food allergy. Part 2: Diagnosis and management. J Allergy Clin Immunol 1999;103:988-989

45. 50. Sampson HA, Scanlon SM. Natural history of food hypersensitivity in children with atopic dermatitis. J Pediatr 1989;115:23-27

46. Потемкина А.М.. Атопический дерматит у детей, профилактика, лечение, диспансеризация. Казань 1999. — 40с.

47. Host A. Cow’s milk protein allergy and intolerance in infancy. Pediatr Allergy Immunol 1994;5:5-36

48. The Handbook of Pediatric Nutrition. Gaithersburg. Aspen Publishers 1993:107-144

49. Schrander JJP, van den Bogart JPH., Forget PP, et al. Cow’s milk protein intolerance in infants under 1 year of age: a prospective epidemiological study. Eur J Pediatr 1993;152:640-644

50. Host A, Husby S, Gjesing B, Larsen JN, et al. Prospective estimation of Ig G, Ig G subclass and Ig E antibodies to dietary protein in infants with cow milk allergy. Allergy 1992;47:218-229

51. Zeiger RS. Use of elemental formulas: Hydrolysates in allergy prevention. Ross Conference 107th: Physiologic/Immunologic Responses to Dietary Nutrients: Role of Elemental and Hydrolysate Formulas in Management of the Pediatric Patient. Ross Products Publishers, Columbus, Ohio, 1998:108-126

52. Конь ИЯ, Денисова СН, Вахрамеева СН. Адаптированные смеси на основе козьего молока в профилактике и лечении непереносимости белков коровьего молока. Детский доктор 2001;1:59-62

53. Kjellman N-IM, Johansson SGO. Soy versus cow’s milk in infants with a biparental history of atopic disease: Development of atopic disease and immunoglobulins from birth to 4 years of age. Clin Allergy 1979;9:347-358

54. Zeiger RS, Sampson HA, Bock SA, et al. Soy allergy in infants and children with IgE-associated cow’s milk allergy. J Pediatr, 1999;113:447–451

55. Денисова СН, Вахрамеева СН, Иванина ЕК, Конно ВИ. Смесь “Нэнни“ в диетотерапии детей с атопическим дерматитом. Вопросы детской диетологии 2003;1:86-89

56. MacDonnald A. Which formula in cow`s milk protein intolerance? The dietitian`s dilemma. Eur J Clin Nutrit 1995;49(Suppl 1):56-63

57. Sampson HA. The immunopathogenic role of food hypersensitivity in atopic dermatitis. Acta Derm Venereol 1992;176:34-37

58. Gil KM, Sampson HA. Psychological and social factors of atopic dermatitis. Allergy 9S:84–89

59. White A, Horne DJ, Varigos GA. Psychological profile of the atopic eczema patient. Australas J Dermatol 1990;31:13-16

60. Scheich G, Florin I, Rudolph R, et al. Personality characteristics and serum IgE level in patients with atopic dermatitis. J Psychosom Res 1993;37:637-642

61. Noren P, Melin L. The effect of combined topical steroids and habit-reversal treatment in patients with atopic dermatitis. Br J Dermatol 1989;121:359-366

62. Melin L, Frederiksen T, Noren P, et al. Behavioural treatment of scratching in patients with atopic dermatitis. Br J Dermatol 1986;115:467-474.

63. Horne DJ, White AE, Varigos GA. A preliminary study of psychological therapy in the management of atopic eczema. Br J Med Psychol 1989;62:241-248

64. Haynes SN, Wilson CC, Jaffe PG, et al. Biofeedback treatment of atopic dermatitis: controlled case studies of eight cases. Biofeedback Self Regul 1979;4:195-209

65. Pene J, Rousset F, Briere F, et al. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferons gamma and alpha and prostaglandin E2. Proc Natl Acad Sci U S A 1988;85:6880-6884

66. Gajewski TF, Fitch FW. Anti-proliferative effect of IFN-gamma in immune regulation. I. IFN-gamma inhibits the proliferation of Th2 but not Th1 murine helper T lymphocyte clones. J Immunol 1988;140:4245-4252

67. Boguniewicz M, Jaffe HS, Izu A, et al. Recombinant gamma interferon in treatment of patients with atopic dermatitis and elevated IgE levels. Am J Med 1990;88:365-370.

68. Hanifin JM, Schneider LC, Leung DYM, et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28:189-197

69. Michils A, Farber CM, Van Vooren JP, et al. Sustained benefit of interferon-alpha therapy and oral hyposensitization in severe atopic dermatitis. Br J Dermatol 1994;130:134-135

70. Torrelo A, Harto A, Sendagorta E, et al. Interferon-alpha therapy in atopic dermatitis. Acta Derm Venereol 1992;72:370-372

71. Jullien D, Nicolas JF, Frappaz A, et al. Alpha interferon treatment in atopic dermatitis. Acta Derm Venereol 1993;73:130-132

72. Paukkonen K, Fraki J, Horsmanheimo M. Interferon-alpha treatment decreases the number of blood eosinophils in patients with severe atopic dermatitis. Acta Derm Venereol 1993;73:141-142

73. Pung YH, Vetro SW, Bellanti JA. Use of interferons in atopic (IgE-mediated) diseases. Ann Allergy 1993;71:234-238

Обсуждение закрыто.

Яндекс.Метрика